March 1, 2017
Lilly buys CoLucid Pharmaceuticals
Eli Lilly has completed acquisition of CoLucid Pharmaceuticals at a price of $46.50 per share through a second-step merger.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
March 1, 2017
Novartis cancer division races to catch up with rivals
Novartis is making progress in its bid to catch rivals developing drugs that harness the immune system to fight cancer, one of its top research scientists and latest recruit from Harvard University told Reuters in an interview
March 1, 2017
Novo Nordisk’s vice president, head of North America leaves
Novo Nordisk’s executive vice president, head of North America Operations and president of Novo Nordisk Inc. Jakob Riis has resigned from the company, and will be replaced by senior vice president for Market Access, Doug Langa.
March 1, 2017
Unioversity College London develops anti-phospholipid syndrome treatment with Abzena’s technology, gets £3.5m grant from the Medical Research Council
A research group from University College London’s (UCL’s) Centre for Rheumatology has been awarded a £3.5m grant from the Medical Research Council (MRC) to continue developing of a new treatment for anti-phospholipid syndrome (APS) which uses Abzena’s proprietary conjugation technology.
March 1, 2017
Genticel, GenKyoTex to form Franco-Swiss NOX inhibitors focused Genkyotex
Euronext-listed Genticel and a privately-held Swiss GenKyoTex biopharmaceutical companies, will come together to become Genkyotex, a listed Franco-Swiss company whose focus will be develping a a pipeline of NOX inhibitors, a new therapeutic class in fibrosis and inflammatory pain.
March 1, 2017
How These Healthcare Stocks are Faring?: Synergy Pharma, Novo Nordisk, Apricus Biosciences, and Sucampo Pharma
According to Deloitte’s 2017 Global Health Care Sector Outlook the challenges of providing and funding healthcare around the world are likely to continue this year due to the rising demands and associated spending of the aging population, the growing prevalence of chronic diseases and comorbidities, the development of costly clinical innovations, increasing patient expectations, and continued economic turbulence.
March 1, 2017
CPhI Istanbul rebrands and relocates into MENA region next year
UBM EMEA announces the rebranding and relocation of CPhI Istanbul into CPhI Middle East & Africa, which will open next year (3-5 September 2018) at ADNEC Centre, Abu Dhabi, United Arab Emirates (UAE).
February 28, 2017
ASIT soon to discuss with US and German regulatory on further development and marketing its grass pollen product
ASIT biotech, a Belgian clinical-stage biopharmaceutical company could soon market its gp-ASIT+ grass pollen product, as it showed positive results in Phase III clinical trial in grass pollen rhinitis.
February 28, 2017
Sienna Biopharmaceuticals hire ex Allergan’s boss as advisor
Former Allergan boss David Pyott signed as special advisor to Sienna Biopharmaceuticals, a privately held, clinical-stage medical dermatology and aesthetics company.
February 28, 2017
TopiVert progresses with testing ulcerative colitis drug
TopiVert Pharma has finished dosing of the first subjects in a Phase 1 study of its oral formulation of TOP1288 for the treatment of ulcerative colitis (UC).